BioCryst Pharmaceuticals Inc (BCRX) stock
BCRXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$7.50+0.05 (+0.67%)
Close on Nov 17, 2026Market cap $1.92BP/E –Yield –
BioCryst Pharmaceuticals total debt
Total debt is short-term plus long-term borrowings on the balance sheet at the end of each period.
BioCryst Pharmaceuticals's total debt was $395.40M at Jun 30, 2026. For fiscal 2025 it was $0, down 100.0% from the year before. The highest annual figure on record is $314.87M in fiscal 2024.
Annual total debt
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $0 | -100.0% |
| FY2024 | Dec 31, 2024 | $314.87M | +3.8% |
| FY2023 | Dec 31, 2023 | $303.23M | +30.9% |
| FY2022 | Dec 31, 2022 | $231.62M | +70.2% |
| FY2021 | Dec 31, 2021 | $136.08M | +13.7% |
| FY2020 | Dec 31, 2020 | $119.74M | – |
| FY2019 | Dec 31, 2019 | $0 | -100.0% |
| FY2014 | Dec 31, 2014 | $30.00M | 0.0% |
| FY2013 | Dec 31, 2013 | $30.00M | 0.0% |
| FY2012 | Dec 31, 2012 | $30.00M | 0.0% |
| FY2011 | Dec 31, 2011 | $30.00M | – |
| FY2010 | Dec 31, 2010 | $0 | – |
Quarterly total debt
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $395.40M | +62.9% |
| Q1 FY2026 | Mar 31, 2026 | $395.20M | +25.3% |
| Q4 FY2025 | Dec 31, 2025 | $0 | -100.0% |
| Q3 FY2025 | Sep 30, 2025 | $194.37M | -38.2% |
| Q2 FY2025 | Jun 30, 2025 | $242.79M | -22.6% |
| Q1 FY2025 | Mar 31, 2025 | $315.41M | +2.2% |
| Q4 FY2024 | Dec 31, 2024 | $314.87M | +3.8% |
| Q3 FY2024 | Sep 30, 2024 | $314.33M | +5.5% |
| Q2 FY2024 | Jun 30, 2024 | $313.82M | +7.0% |
| Q1 FY2024 | Mar 31, 2024 | $308.48M | +32.7% |
| Q4 FY2023 | Dec 31, 2023 | $303.23M | +30.9% |
| Q3 FY2023 | Sep 30, 2023 | $298.00M | +33.1% |
| Q2 FY2023 | Jun 30, 2023 | $293.18M | +102.9% |
| Q1 FY2023 | Mar 31, 2023 | $232.52M | +65.8% |
| Q4 FY2022 | Dec 31, 2022 | $231.62M | +70.2% |
| Q3 FY2022 | Sep 30, 2022 | $223.87M | +69.5% |
| Q2 FY2022 | Jun 30, 2022 | $144.52M | +14.0% |
| Q1 FY2022 | Mar 31, 2022 | $140.24M | +14.0% |
| Q4 FY2021 | Dec 31, 2021 | $136.08M | +13.7% |
| Q3 FY2021 | Sep 30, 2021 | $132.05M | – |
| Q2 FY2021 | Jun 30, 2021 | $126.80M | – |
| Q1 FY2021 | Mar 31, 2021 | $123.04M | – |
| Q4 FY2020 | Dec 31, 2020 | $119.74M | – |
| Q4 FY2019 | Dec 31, 2019 | $0 | – |
See a number that looks wrong?